Actelion
Clinical trials sponsored by Actelion, explained in plain language.
A pharmaceutical company focused on pulmonary hypertension, now part of Johnson & Johnson.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could this pill help kids with rare lung disease?
Disease control OngoingThis study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH). About 138 children will receive either selexipag or a placebo, plus their usual medications. The main goal is to see if…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could a new dose of selexipag help kids with rare lung disease?
Disease control OngoingThis study is testing the safety and right dose of a drug called selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal is to find a dose that works like the adult version. The stu…
Phase: PHASE2 • Sponsor: Actelion • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Higher dose of PAH drug may keep patients out of hospital longer
Disease control OngoingThis phase 3 trial compares two doses of macitentan (75 mg vs 10 mg) in about 935 adults with pulmonary arterial hypertension. The goal is to see if the higher dose can delay serious events like hospitalization or death. Participants will be followed for several years.
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for rare disease patients with Non-Healing wounds
Disease control APPROVED_FOR_MARKETINGThis program offers selexipag (Uptravi) to a single patient with Buerger's disease who has a wound that won't heal. The goal is to see if the drug can help control the disease and improve wound healing. This is not a cure, and the patient may need ongoing treatment.
Sponsor: Actelion • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC